Filing Details

Accession Number:
0000921895-23-001420
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-06-02 17:03:18
Reporting Period:
2023-06-01
Accepted Time:
2023-06-02 17:03:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1829802 Sensei Biotherapeutics Inc. SNSE () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1828422 Presight Sensei Co-Invest Fund, L.p. 340 S. Lemon Ave., # 3391
Walnut CA 91789
No No No Yes
1845711 Ltd. Group Investment Apeiron Beatrice, At 66 &Amp; 67 Amery Street
Sliema O1 SLM1707
No No Yes No
1845872 Christian Angermayer Beatrice, At 66 &Amp; 67 Amery Street
Sliema O1 SLM1707
No No Yes No
1846009 Presight Co-Invest Management, L.l.c. 340 S. Lemon Ave. #3391
Walnut CA 91789
No No No Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-06-01 2,485,923 $1.58 0 No 4 S Indirect By Apeiron Investment Group Ltd.
Common Stock Disposition 2023-06-01 955,738 $1.58 0 No 4 S Indirect By Presight Sensei Co-Invest Fund, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Apeiron Investment Group Ltd.
No 4 S Indirect By Presight Sensei Co-Invest Fund, L.P.
Footnotes
  1. This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
  2. Securities owned directly by Apeiron. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Apeiron.
  3. Securities owned directly by Presight Co-Invest. As the general partner of Presight Co-Invest, Presight Co-Invest Management may be deemed to beneficially own the securities owned directly by Presight Co-Invest. As the sole member of Presight Co-Invest Management, Apeiron may be deemed to beneficially own the securities owned directly by Presight Co-Invest. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Presight Co-Invest.